Clinical Trial Search

Primary: Mean Change in Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity at 104 Weeks From Day 0. — -1.9; -3.9; 1.3 letters

Primary: Mean Best Corrected Visual Acuity (BCVA) in Patients Treated With Intravitreal Aflibercept Injections for the Management of Radiation Maculopathy. — 0.425; 0.548 Log MAR…

Primary: Corneal Thickness — 542.23; 546.16; 544.32 microns

Primary: Incidence and Severity of Ocular Adverse Events — 0 number of adverse events

Primary: Rate of Retinal Attachment — 50; 42 Participants

Primary: Number of Patients Experiencing Feasibility Failure — 4 participants

Primary: Time-averaged Effect on Radiation Dermatitis Grade Measured With Common Terminology Criteria for Adverse Events (CTCAE, v 4.03) Following 3D Conformal Radiation Therapy…

Primary: Height (Amplitude) of Multifocal ERG Signal — 2.859 nanovolt/degree^2 — p=<0.05

Primary: The Mean Percentage Change of the Area of the Patient's Neovascularization as Measured in Pixels by Optomap FA (Fluorescein Angiography) — -83.8; 52.6; 11.3; 55.4…

Primary: Stratum B Response to Window Therapy — 24; 2; 1 Participants

Primary: Visual Acuity — 16.8; 14.5; 19.1; 15.3 letters on ETDRS Visual Acuity Chart

Primary: Change in Electronic Early Treatment Diabetic Retinopathy Study Visual Acuity Letter Score From Baseline to 14 Weeks — -4; 1; 2 Letter Score — p=<.001

Primary: Event-free Survival (EFS) — 88; 83; 28 Probability

Primary: Mean Change in Early Treatment for Diabetic Retinopathy Study (ETDRS) Best-corrected Visual Acuity (BCVA) From Baseline to Month 12 — -4.8; -0.9 ETDRS Letters

Primary: Number of Participants With Progression of Diabetic Retinopathy of at Least 3 Stages on the Early Treatment Diabetic Retinopathy Study (ETDRS) Scale, or Development of…

Primary: Mean Number of Retreatments (Day 0 Excluded) — 3.97; 3.00; 4.05; 5.39 number of retreatments

Primary: Sensitivity(mtmDR) — 90.48; 95.65; 95.19 percentage of true positives

Primary: Change in Panretinal Leakage Index at Month 12 From Baseline — -3.14 percentage of region of interest in UWFA

Primary: Mean Change in Cone Spacing in Arcminutes (Z Score) of 2 Baseline Values Were Compared With Measurements Obtained at Post-op Month 36 — 1.13; 0.85 Difference in change…

Primary: Percentage of Participants With Absence of Active ROP and Absence of Unfavorable Structural Outcomes in Both Eyes at Week 24 — 80.0; 75.0; 66.2 Percentage of…

Primary: Percent of Eyes With Severe Ocular Adverse — 0; 0; 0 percentage of participants

Primary: Total Number of Intravitreal Injections Over a 12 Month Period — 8.7; 9.5 injections

Primary: Percentage of Participants With Improvement in DRSS by ≥ 2 Steps at 48 Weeks of Treatment in the Study Eye — 0.0; 1.9 percentage of participants

Primary: Number of Participants With Complete Response (CR) or Partial Response (PR) — 10; 2 participants

Primary: Proportion of Participants With Absence of Active ROP and Unfavorable Structural Outcomes — 0.855; 0.821 Proportion of participants

Primary: Change in Macular Drusen Volume — 0.05; 0.11; 20.0; 9.0 mm^3

Primary: Caliber of Choroidal New Vessel (CNV) — 43.53 micrometer

Primary: Percentage of Participants With Absence of Active Retinopathy of Prematurity (ROP) and Unfavorable Structural Outcomes From Baseline to Week 52 of Chronological Age…

Primary: Mean Change in Visual Acuity From Baseline — 2.8; 0.2 letters

Primary: Per Patient Referral Accuracy — 318 Participants